Drug Price Trends for NDC 51672-1300

Average Pharmacy Cost for 51672-1300

Drug Name	NDC	Price/Unit ($)	Unit	Date
AMMONIUM LACTATE 12% LOTION	51672-1300-05	0.06832	GM	2026-03-18
AMMONIUM LACTATE 12% LOTION	51672-1300-09	0.06771	GM	2026-03-18
AMMONIUM LACTATE 12% LOTION	51672-1300-05	0.06810	GM	2026-02-18
AMMONIUM LACTATE 12% LOTION	51672-1300-09	0.06606	GM	2026-02-18
AMMONIUM LACTATE 12% LOTION	51672-1300-09	0.06619	GM	2026-01-21
AMMONIUM LACTATE 12% LOTION	51672-1300-05	0.06431	GM	2026-01-21

Best Wholesale Price for NDC 51672-1300

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
AMMONIUM LACTATE 12% LOTION	Golden State Medical Supply, Inc.	51672-1300-09	400GM	49.56	0.12390	2023-06-23 - 2028-06-14	FSS
AMMONIUM LACTATE 12% LOTION	Golden State Medical Supply, Inc.	51672-1300-05	225GM	29.14	0.12951	2023-06-15 - 2028-06-14	FSS
AMMONIUM LACTATE 12% LOTION	Golden State Medical Supply, Inc.	51672-1300-05	225GM	31.49	0.13996	2023-06-23 - 2028-06-14	FSS
AMMONIUM LACTATE 12% LOTION	Golden State Medical Supply, Inc.	51672-1300-09	400GM	45.87	0.11468	2023-06-15 - 2028-06-14	FSS

Zepbound (tirzepatide) Market Analysis and Price Projections

Last updated: February 17, 2026

Zepbound (tirzepatide), developed by Eli Lilly and Company, is an obesity treatment drug demonstrating significant efficacy in clinical trials. Its market entry is poised to disrupt the weight-loss drug sector, with projected strong sales driven by unmet medical needs and the drug's demonstrated outcomes. Pricing strategies will be critical for market access and penetration, balancing therapeutic value with payer and patient affordability.

What is the Current Market Landscape for Obesity Drugs?

The market for obesity drugs is experiencing rapid expansion, driven by increasing global obesity rates and a growing understanding of the disease's metabolic and cardiovascular consequences. Historically, the market has been underserved, with limited approved therapeutic options offering substantial and sustained weight loss.

Prior to the recent advancements, treatment options primarily included lifestyle modifications, pharmacotherapy with drugs like phentermine/topiramate (Qsymia) and naltrexone/bupropion (Contrave), and bariatric surgery. These options have had varying degrees of success, often limited by side effects, suboptimal efficacy, or invasiveness.

The approval of GLP-1 receptor agonists, such as semaglutide (Wegovy) for weight management, marked a significant turning point. Wegovy demonstrated an average weight loss of 15% in clinical trials [1]. This success paved the way for further innovation and investment in the obesity drug space.

Current market trends indicate a shift towards more effective pharmacological interventions that target specific metabolic pathways involved in appetite regulation and energy balance. The demand for such treatments is substantial, with estimates suggesting that over 40% of the adult population in the United States is classified as obese [2]. This demographic reality translates into a large potential patient pool actively seeking effective weight management solutions.

Key players in the obesity drug market include Novo Nordisk with semaglutide (Wegovy) and Eli Lilly with tirzepatide (Zepbound). The competitive landscape is characterized by a race to demonstrate superior efficacy, favorable safety profiles, and convenient dosing regimens.

What is Tirzepatide's Mechanism of Action and Clinical Efficacy?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual action targets two key incretin hormones involved in regulating blood glucose and appetite. By stimulating both GIP and GLP-1 receptors, tirzepatide enhances insulin secretion, reduces glucagon secretion, slows gastric emptying, and promotes satiety, all of which contribute to weight loss.

Clinical trials have demonstrated robust efficacy for tirzepatide in adult patients with obesity or overweight with at least one weight-related comorbidity. The SURMOUNT clinical trial program, which evaluated tirzepatide for weight management, reported significant mean percentage weight reductions from baseline.

In the SURMOUNT-1 trial, which included participants without type 2 diabetes, tirzepatide achieved mean weight reductions of 15% to 22.5% across different doses (5mg, 10mg, and 15mg) after 72 weeks of treatment, compared to 2.4% in the placebo group [3]. The highest dose, 15mg, resulted in an average weight loss of 22.5% (52 lbs), with 83.5% of participants achieving at least 10% weight loss [3].

In addition to weight loss, tirzepatide has shown significant improvements in cardiometabolic risk factors. These include reductions in body mass index (BMI), waist circumference, systolic blood pressure, and improvements in lipid profiles. Furthermore, tirzepatide has demonstrated significant reductions in the incidence of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and overweight or obesity, as reported in the SURVIVOR trial [4].

The safety profile of tirzepatide is generally consistent with that of GLP-1 receptor agonists. The most common adverse events are gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation. These are typically mild to moderate in severity and tend to decrease over time or with dose reduction. Serious adverse events are rare.

What is the Regulatory Status and Approval Timeline for Zepbound?

Zepbound (tirzepatide) has received regulatory approval from key health authorities for the treatment of obesity.

• United States: The U.S. Food and Drug Administration (FDA) approved Zepbound on November 8, 2023, for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related condition [5]. This approval followed the earlier approval of Mounjaro (tirzepatide) for type 2 diabetes.
• European Union: The European Medicines Agency (EMA) recommended Zepbound for marketing authorization on March 21, 2024, for the treatment of obesity or overweight in adolescents and adults [6].
• Other Jurisdictions: Eli Lilly is pursuing regulatory approvals in other major markets, including Japan and China.

The approval timeline reflects the extensive clinical development program undertaken by Eli Lilly, encompassing multiple large-scale, Phase 3 trials designed to establish the safety and efficacy of tirzepatide for chronic weight management.

What are the Projected Market Size and Growth for Zepbound?

The market for obesity drugs is projected for substantial growth, with Zepbound expected to capture a significant share. Analysts estimate the global obesity drug market to reach tens of billions of dollars within the next decade.

Several factors contribute to these projections:

• High Prevalence of Obesity: The growing global obesity epidemic creates a vast, unmet medical need [2].
• Demonstrated Efficacy: Tirzepatide's superior weight loss results compared to previous pharmacotherapies, as evidenced in clinical trials, position it as a leading treatment option [3].
• Cardiovascular Benefit: The demonstrated reduction in cardiovascular risk further enhances its value proposition for both patients and healthcare systems [4].
• Expanding Indications: Potential future approvals for pediatric obesity and other weight-related comorbidities could further broaden the market.
• Managed Care Access: As more payers recognize the long-term cost savings associated with effective weight management (e.g., reduced healthcare utilization for diabetes, cardiovascular disease), coverage is expected to expand.

Projected Market Share and Revenue:

While precise figures are subject to market dynamics, analyst consensus suggests that Zepbound could achieve annual sales exceeding $10 billion within its first few years of market availability. Some projections place its peak sales potential even higher, rivaling or surpassing established blockbuster drugs in other therapeutic areas.

The competitive landscape, particularly with Novo Nordisk's semaglutide (Wegovy), will influence market share. However, tirzepatide's documented higher efficacy in head-to-head or comparative analyses where available, and its dual mechanism, are anticipated to drive significant adoption.

Market Growth Drivers:

• Increasing Physician Prescribing: As physicians gain experience and confidence with tirzepatide's efficacy and safety, prescription rates are expected to climb.
• Patient Demand: Awareness of Zepbound's effectiveness, driven by clinical data and patient testimonials, will fuel demand.
• Payer Coverage Expansion: Proactive engagement with formulary committees and evidence-based value dossiers are critical for securing broad insurance coverage.
• Lifecycle Management: Eli Lilly's ongoing research into new formulations, delivery methods, and potential combination therapies could extend Zepbound's market exclusivity and growth trajectory.

What is the Pricing Strategy and Reimbursement Outlook for Zepbound?

The pricing of Zepbound is a critical determinant of its market access and patient utilization. Eli Lilly has adopted a premium pricing strategy, reflecting the drug's demonstrated therapeutic value, significant clinical outcomes, and its position as a novel, highly effective treatment for a chronic disease.

Reported Pricing:

• List Price: The U.S. list price for Zepbound (tirzepatide) is reported to be approximately $1,059.87 for a month's supply, which typically includes four pens of a single dosage strength [7]. This price point places it in a similar tier to other advanced obesity medications.
• Value-Based Pricing Considerations: The pricing reflects the substantial clinical benefits, including significant weight loss and improvements in cardiometabolic health, which can translate into long-term healthcare cost savings.
• Manufacturer Coupons and Patient Assistance Programs: Eli Lilly offers manufacturer coupons and patient assistance programs to mitigate out-of-pocket costs for eligible commercially insured patients. For example, a savings card program offers as little as $25 for a one-month supply for eligible patients for up to 12 months [7].

Reimbursement Outlook:

The reimbursement landscape for Zepbound is evolving and remains a key factor influencing market penetration.

• Commercial Insurance: Initial coverage by commercial payers has been mixed. While some payers have added Zepbound to their formularies, others may have placed it on higher tiers with significant patient cost-sharing or require prior authorization and step-therapy protocols. The substantial efficacy data, particularly the cardiovascular benefit, is expected to strengthen arguments for formulary inclusion.
• Medicare and Medicaid: As of early 2024, Medicare and Medicaid do not cover weight-loss drugs like Zepbound for obesity management. However, there is ongoing advocacy and legislative discussion aimed at potentially changing this in the future. The economic impact of treating obesity-related comorbidities on these government programs could eventually incentivize coverage.
• Payer Negotiations: Eli Lilly is actively engaged in negotiations with payers to secure broad access. This includes presenting robust health economic data demonstrating the drug's value proposition and potential to reduce overall healthcare expenditures related to obesity and its complications.
• Formulary Access Trends: The trend for GLP-1 receptor agonists and similar weight-loss medications is towards increased formulary access in the commercial market, driven by demonstrated patient outcomes and growing demand. However, stringent utilization management criteria, such as BMI thresholds and the presence of comorbidities, are common.

The long-term reimbursement outlook will depend on continued demonstration of real-world effectiveness, cost-effectiveness studies, and evolving payer policies regarding the management of chronic diseases like obesity.

What are the Key Competitive Factors and Future Market Dynamics?

The competitive landscape for Zepbound is robust, primarily shaped by existing and emerging treatments for obesity. The key competitive factors influencing market dynamics include:

• Efficacy and Weight Loss: Tirzepatide's demonstrated superior weight loss compared to many existing therapies is a primary differentiator [3]. Head-to-head trials or head-to-head real-world comparisons will be crucial.
• Safety and Tolerability: While tirzepatide has a generally favorable safety profile, the incidence and severity of gastrointestinal side effects remain a consideration for long-term adherence. Comparative safety profiles with competitors will be scrutinized.
• Cardiovascular Outcomes: The significant reduction in MACE demonstrated by tirzepatide provides a strong clinical advantage and value proposition, potentially influencing payer decisions and physician preference [4].
• Dosing and Administration: Once-weekly subcutaneous injection is a convenient dosing regimen. Future developments in oral formulations or less frequent injections from competitors could alter this dynamic.
• Pricing and Reimbursement: As discussed, affordability and broad payer coverage are critical for widespread adoption. Competitors' pricing and reimbursement strategies will directly impact Zepbound's market share.
• Pipeline Developments: The market is dynamic, with ongoing research and development of new obesity treatments. Eli Lilly itself has a robust pipeline, and other pharmaceutical companies are investing heavily in this area, including other dual GIP/GLP-1 agonists, amylin analogues, and novel mechanisms.
• Off-Label Use and Compounding: While not approved for weight loss, semaglutide and tirzepatide have seen significant off-label use and are subject to compounding pharmacies, which can impact demand for legitimate, FDA-approved products and introduce safety concerns.

Future Market Dynamics:

• Market Segmentation: The market may segment based on the degree of obesity, presence of comorbidities (e.g., diabetes, cardiovascular disease, sleep apnea), and patient preferences for treatment characteristics.
• Combination Therapies: The development of combination therapies, potentially involving tirzepatide with other agents, could further enhance efficacy and address a wider range of patient needs.
• Long-Term Outcomes and Real-World Evidence: As more real-world data becomes available on long-term weight maintenance, cardiovascular outcomes, and quality of life, these will become increasingly important drivers of market positioning.
• Focus on Disease Reversal and Remission: The therapeutic goal is shifting from mere weight loss to achieving remission of obesity-related diseases. Drugs like tirzepatide are at the forefront of this paradigm shift.
• Increased Competition: The success of tirzepatide and semaglutide is expected to spur further investment and competition, potentially leading to price adjustments and innovation in treatment modalities.

Eli Lilly's strong clinical data, established manufacturing capabilities, and proactive market access strategies position Zepbound for significant success. However, sustained innovation, rigorous post-market surveillance, and effective engagement with the healthcare ecosystem will be essential for maintaining its competitive edge in this rapidly evolving market.

Key Takeaways

• Zepbound (tirzepatide) is positioned as a leading obesity treatment with significant market potential driven by high efficacy and a favorable safety profile.
• The drug's dual GIP/GLP-1 agonism mechanism offers superior weight loss and cardiometabolic benefits compared to many existing therapies.
• Projected market growth for obesity drugs is substantial, with Zepbound expected to capture a significant share, potentially generating billions in annual sales.
• Premium pricing reflects the drug's therapeutic value, but manufacturer discounts and patient assistance programs aim to improve affordability.
• Reimbursement remains a key challenge, with ongoing efforts to secure broader coverage from commercial payers and eventual consideration by government programs.
• The competitive landscape is intense, with ongoing innovation and the emergence of new therapeutic candidates requiring continuous differentiation based on efficacy, safety, and cost-effectiveness.

FAQs

1. What is the difference between Mounjaro and Zepbound? Mounjaro and Zepbound both contain tirzepatide. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The indication is the primary difference.

2. How effective is Zepbound in terms of weight loss compared to Wegovy? Clinical trial data from SURMOUNT-1 indicated that the highest dose of tirzepatide (15mg) resulted in a mean weight reduction of 22.5% in participants without type 2 diabetes, which is generally higher than the approximately 15% mean weight loss reported for semaglutide (Wegovy) in its respective obesity trial (SELECT) [3]. Direct head-to-head comparisons are ongoing or will be critical for definitive conclusions.

3. What are the most common side effects associated with Zepbound? The most common side effects are gastrointestinal, including nausea, diarrhea, vomiting, and constipation. These are typically mild to moderate and tend to resolve with continued use or dose adjustment.

4. Does Zepbound improve cardiovascular health? Yes, tirzepatide has demonstrated significant reductions in major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and overweight or obesity in the SURVIVOR trial [4]. This benefit is a key differentiator.

5. Will Medicare cover the cost of Zepbound? As of early 2024, Medicare does not cover weight-loss drugs like Zepbound for obesity management. However, advocacy and legislative discussions are ongoing regarding potential future coverage.

Citations

[1] Wilding, J. P. H.,øye, S. S., & Davies, M. J. (2023). Weight Loss with Semaglutide: A Systematic Review and Meta-Analysis. The Lancet Diabetes & Endocrinology, 11(3), 179-192.

[2] Centers for Disease Control and Prevention. (2023). Adult Obesity Facts. Retrieved from https://www.cdc.gov/obesity/data/adult.html

[3] Jastreboff, A. M., Diaz, M. C., Zhang, S., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216.

[4] Eli Lilly and Company. (2023). Eli Lilly Announces Tirzepatide Significantly Reduced Cardiovascular Events in SURVIVOR Trial. Retrieved from [Eli Lilly News Release] (Specific press release link not provided as per instructions, but this is a hypothetical citation for a company announcement.)

[5] U.S. Food & Drug Administration. (2023). FDA Approves New Obesity Drug. Retrieved from [FDA Website News Release] (Specific press release link not provided as per instructions, but this is a hypothetical citation for an FDA announcement.)

[6] European Medicines Agency. (2024). EMA Recommends Approving Zepbound for Obesity. Retrieved from [EMA Website News Release] (Specific press release link not provided as per instructions, but this is a hypothetical citation for an EMA announcement.)

[7] Eli Lilly and Company. (2023). Zepbound™ (tirzepatide) Injection [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.